INTRODUCTION
============

Asthma is a chronic airway disease with the symptoms of repetitive cough, wheezing and dyspnea, with reversible airway narrowing accompanied by airway hyper-responsiveness ([@B25]). It is estimated that worldwide, approximately 300 million people including both children and adults have asthma ([@B22]). Inhaled irritants, inhaled allergens, and microorganism infections of the respiratory tract are common causes of asthma exacerbations. Respiratory viral infection is closely associated with asthma ([@B15]; [@B26]). Human rhinovirus (HRV) is the most common virus in asthmatics of all ages ([@B26]). Respiratory syncytial virus and enterovirus are also frequently detected in infants, whereas influenza virus seems to induce severe exacerbations, mostly in adults ([@B26]).

Influenza virus causes influenza characterized by a sudden onset of high fever and respiratory symptoms such as cough, sore throat and coryza, as well as systemic symptoms such as headache, muscle ache and fatigue. Influenza epidemics occur yearly during the autumn and winter in temperate regions, whereas the disease patterns in tropical and subtropical regions are less well established ([@B33]). Annual epidemics result in approximately three to five million cases of severe illness and approximately 250,000 to 500,000 deaths, which occur mostly among people age 65 or older ([@B33]).

INFLUENZA A(H1N1)pdm09 VIRUS
============================

Influenza A viruses can be subtyped according to their two major surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA). Currently, there are 16 subtypes of HA (H1--H16) and nine subtypes of NA (N1--N9), and all have been found in wild aquatic birds, which are the natural reservoir of influenza A viruses. Only two subtypes of these viruses (H1N1 and H3N2) are currently circulating in humans, as seasonal influenza. Influenza A viruses have negative-sense, single-stranded, and eight-segmented RNAs as the genome ([@B20]). It is known that simultaneous infection of a single cell by two distinct influenza A viruses can lead to gene reassortment ([@B14]), which results in the generation of a novel influenza virus strain. It is believed that most human pandemic influenza A viruses arose in this manner.

In March and early April 2009, a novel swine-origin influenza A(H1N1) virus, designated as A(H1N1)pdm09, emerged in Mexico and the United States ([@B8]) and rapidly spread worldwide. Genetic and evolutionary analyses revealed that this pandemic virus contains a combination of gene segments which had not been reported previously in swine or human influenza viruses in any part of the world. In the late 1990s, reassortment among North American avian (unknown subtype), human A(H3N2), and classical swine A(H1N1) viruses resulted in triple reassortant swine A(H3N2) and A(H1N2) viruses.

A triple reassortant swine A(H1N2) virus then reassorted with a Eurasian avian-like swine A(H1N1) virus, resulting in A(H1N1)pdm09 virus ([@B11]; [@B30]; **Figure [1](#F1){ref-type="fig"}**). The polymerase basic 2 (PB2) and polymerase acidic (PA) gene segments were derived from the avian virus lineage, whereas the polymerase basic 1 (PB1) gene segment was from human A(H3N2) virus. The HA, nucleoprotein (NP), and non-structural protein (NS) gene segments were from classical swine A(H1N1) virus. The NA and matrix (M) gene segments were from the Eurasian avian-like swine A(H1N1) virus.

![**A(H1N1)pdm09 virus and asthma.** The reassortment of a triple reassortant swine A(H1N2) virus with a Eurasian avian-like swine A(H1N1) virus resulted in the pandemic A(H1N1) 2009 virus. The colored solid rods represent the gene segments as follows. Classical swine A(H1N1) virus: red. North American avian virus: yellow. Human A(H3N2) virus: green. Eurasian avian-like swine A(H1N1) virus: purple. Airway inflammation induced by the viral infection causes an exacerbation of asthma. Early treatment with antiviral drugs and vaccination represents the mainstay of management.](fmicb-04-00307-g001){#F1}

A(H1N1)pdm09 virus has none of the known hallmarks of virulent influenza viruses such as highly pathogenic avian A(H5) and A(H7) viruses, except for an amino acid substitution of aspartic acid by glycine at position 222 (D222G) in the HA, which was observed in severe and fatal cases with high frequency. The D222G substitution changes the receptor binding specificity of the virus from α2--6 (mammalian type) to α2--3 (avian type) sialylated glycans ([@B27]; [@B34]; [@B4]). This amino acid substitution may result in a more efficient infection of human alveolar type II pneumocytes, which express avian type receptors, reducing the availability of progenitor cells for essential lung functions and thus leading to severe pulmonary impairment.

We recently reported that A(H1N1)pdm09 viral isolates derived from fatal cases manifested sporadic amino acid changes in the PB2 and PA proteins (which are subunits of viral RNA polymerase) more frequently than those derived from mild cases ([@B24]). More recently, reassortant viruses generated by reverse genetics have shown that lysine or isoleucine at position 340 or 649 of the PB2, respectively, and threonine at position 667 of the PB2 also contribute to virulence in a mouse model ([@B31]). Further studies are needed to elucidate the role of the viral RNA polymerase of A(H1N1)pdm09 virus as a virulence factor.

A(H1N1)pdm09 VIRAL INFECTION AND ASTHMA
=======================================

Widespread activity of pandemic A(H1N1) 2009 occurred and reached its peak a couple of months earlier than the usual seasonal influenza in the northern hemisphere, from April 2009 to January 2010 ([@B1]; [@B17]). The A(H1N1)pdm09 viral infection was considered a mild disease, similar to seasonal influenza. However, many severe and fatal cases were observed not only in the high-risk groups, but also among healthy children and young adults during the pandemic waves ([@B3]; [@B28]).

Asthma was one of the most common underlying medical conditions among patients hospitalized with A(H1N1)pdm09 viral infection in 2009 worldwide ([@B16]; [@B32]). [@B18] reported that children with asthma had increased susceptibility to A(H1N1)pdm09 viral infection. They collected weekly nasal samples from 161 children (95 with asthma and 66 without asthma) between September 5 and October 24, 2009, and a total of 346 viral infections were detected. The majority were HRV (62%), followed by enterovirus (12%), A(H1N1)pdm09 virus (10%), adenovirus (2%), and others. Overall, 34% of the children were infected with A(H1N1)pdm09 virus during the study period. The incidence of A(H1N1)pdm09 viral infection was significantly higher in the children with asthma (41%) than in the children without asthma (24%), whereas the incidences of HRV (95% each) and the other viral infections (47% vs. 41%) were similar.

A Canadian group reported that children admitted to a hospital with A(H1N1)pdm09 viral infection tended to have pre-existing asthma to a greater extent compared to the children with seasonal influenza A viral infection (15% vs. 5%), although there was no significant difference in the severity of pre-existing asthma between the groups of children with these infections ([@B23]). An age-matched control study in Hong Kong demonstrated that hospitalized children with A(H1N1)pdm09 viral infection were more susceptible to asthma exacerbations compared to seasonal A(H1N1) (8.1 vs. 1.0%) or A(H3N2) (8.1 vs. 1.0%) viral infection ([@B9]). A Japanese group reported similar findings ([@B13]). It seems likely that A(H1N1)pdm09 viral infection rather than A(H1N1) or A(H3N2) viral infection may enhance the already elevated inflammatory response and worsen the symptoms in asthma. The underlying mechanisms of increased susceptibility to A(H1N1)pdm09 viral infection and the asthma exacerbation remain to be explored.

In contrast, it is not clear whether A(H1N1)pdm09 viral infection can frequently cause the development of asthma compared to seasonal A(H1N1) or A(H3N3) viral infection. The study by [@B13] mentioned above showed that 7 (31.8%) of 22 asthmatic children with A(H1N1)pdm09 viral infection admitted to a hospital between October and December 2009 were not previously diagnosed with asthma. The sample size of that study is small, and thus a larger patient population must be studied.

Influenza A viral infection induces the production of interleukin 1 beta (IL-1β), IL-6, IL-8, tumor necrosis factor-alpha (TNF)-α, histamine, protease, interferon (IFN)-α, and IFN-gamma (IFN-γ) from airway epithelial cells and other cells including peripheral blood basophils ([@B38]). These proinflammatory cytokines, monokines, and inflammatory substances may contribute to the development of airway inflammation, damaging the barrier function and leading to a subsequent asthma attack (**Figure [1](#F1){ref-type="fig"}**).

[@B6] examined the phenotypic differences in virulence and immune response in A(H1N1)pdm09 virus isolates obtained from hospitalized patients with severe pneumonia. In that study, all viral isolates showed high similarity in nucleic acid sequences in viral gene and replication levels in nasal turbinates and lung, but the isolates' virulence and host responses in mice varied. Proinflammatory cytokines such as IL-1β, TNF-α and a keratinocyte-derived chemokine (KC) were expressed early in mice infected with virulent isolates compared to avirulent isolates, including a vaccine strain of A(H1N1) virus in the 2008--2009 season, A/Brisbane/59/2007. In vitro experiments demonstrated that a virulent isolate -- but not an avirulent isolate -- was able to replicate productively in macrophages, suggesting that viral susceptibility to macrophages may be one of the key determinants of their pathogenicity ([@B6]).

UTILITY OF INFLUENZA VACCINES AND ANTIVIRAL DRUGS IN PATIENTS WITH ASTHMA
=========================================================================

Many respiratory viruses are associated with asthma exacerbations, among which the influenza virus is the only virus for which both vaccines and antiviral drugs are available (**Figure [1](#F1){ref-type="fig"}**). Two types of influenza vaccines are currently available; inactivated vaccine and live, attenuated vaccine. The live, attenuated nasal-spray influenza vaccine has been approved for use in the United States since 2003. However, it has not been recommended in high-risk groups including asthmatics because its safety is not fully demonstrated. The widespread use of inactivated influenza vaccines contain a trivalent mixture of strains of A(H1N1)pdm09, A(H3N2), and type B viruses likely to circulate during the next influenza season. Many studies indicated that no increase in asthma exacerbations was reported for both vaccinated children and adults ([@B2]; [@B19]; [@B12]).

A randomized, open-label study to investigate the safety and immunogenicity of two administrations of an unadjuvanted, inactivated A(H1N1)pdm09 virus vaccine was conducted in the United States ([@B5]). The results indicated that both the 15-μg (standard dose) and 30-μg vaccine doses generally provided excellent seroprotection against viral antigen 21 days after a single immunization in patients (12 to 79 years of age) with mild-to-moderate asthma. In patients with severe asthma, the response to the 15-μg dose was lower than that to the 30-μg dose. The authors of that study did not identify any safety concerns with the A(H1N1)pdm09 vaccine. Collectively, the findings described above indicate that inactivated influenza vaccines are well tolerated in patients with asthma.

Specific antiviral drugs against influenza viruses could be used for the treatment and prophylaxis for influenza. Based on their chemical properties and spectra of activity against influenza viruses, the drugs can be classified into two categories: the M2 ion channel inhibitors, i.e., adamantanes (amantadine and rimantadine) and the NA inhibitors, i.e., zanamivir, oseltamivir, peramivir, and laninamivir. Currently, the NA inhibitors are exclusively used for the treatment and prophylaxis of influenza because the circulating strains of A(H1N1)pdm09 and A(H3N2) viruses have a known amino acid substitution of serine by asparagines at position 31 in the M2 protein, which confers resistance to the adamantanes.

Few studies have examined the safety of NA inhibitors in patients with asthma. A double-blind, placebo-controlled crossover study indicated that zanamivir inhaled as a dry powder did not significantly affect the pulmonary function and airway responsiveness of subjects (19 to 49 years of age) with mild or moderate asthma ([@B7]). However, a number of studies suggested that the use of NA inhibitors was beneficial in hospitalized patients with A(H1N1)pdm09 viral infection, particularly when they are started within 48 h after the onset of illness ([@B10]; [@B16]; [@B21]). Accordingly, WHO recommended that for patients at increased risk for severe or complicated illness, treatment with oseltamivir or zanamivir should be started as soon as possible after the onset of illness ([@B37]). Although A(H1N1)pdm09 virus resistance to NA inhibitors has been detected at very low frequency among circulating viral strains ([@B36]), there is concern about the recent report that oseltamivir-resistant A(H1N1)pdm09 viral mutants were detected in untreated patients and from a few clusters in some countries ([@B29]).

CLOSING REMARKS
===============

Epidemiological studies as described above demonstrated that A(H1N1)pdm09 viral infection is closely associated with asthma in both children and adults. Although A(H1N1)pdm09 virus has not shown a high mortality rate similar to that of the highly pathogenic avian influenza virus of the H5N1 subtype, patients with A(H1N1)pdm09 viral infection were more susceptible to asthma exacerbation compared to A(H1N1) or A(H3N2) viral infection. Detailed analyses of virus-host interactions are needed to elucidate the mechanism underlying A(H1N1)pdm09 viral infection-induced asthma.

Since March 31, 2013 when the public health authorities of China reported three cases of human infection with an avian influenza A(H7N9) virus, a total of 135 human cases including 44 fatal cases have been reported in China and Taiwan as of August 12, 2013 ([@B35]). The current avian influenza viral infections in humans present considerable pathogenic potential with high mortality rates, suggesting that the pandemic viruses, if they emerge in human beings, could also present high pathogenicity and result in an excessive number of deaths in high-risk groups, including asthmatics. It will therefore be important to make preparations for drugs and vaccines for anti-influenza treatments and the prophylaxis of influenza.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

This work was supported in part by a Grant-in-Aid for Research on Emerging and Re-emerging Infectious Diseases, Labour and Welfare Programs from the Ministry of Health, Labour and Welfare of Japan (H24-Shinko-Ippan-014).

[^1]: Edited by: *Hirokazu Kimura, National Institute of Infectious Diseases, Japan*

[^2]: Reviewed by: *Jianwei Wang, Chinese Academy of Medical Sciences, Peking Union Medical College, China; Wei Zhang, Yele University, USA*

[^3]: This article was submitted to Virology, a section of the journal Frontiers in Microbiology.
